Champix Class Action Lawsuit

Champix Image

Notice of Discontinuance of Champix Class Action

By order of the Ontario Superior Court of Justice, dated April 20, 2017, the certified class action lawsuit, Parker v. Pfizer Canada Inc, (Ontario Court File No: CV-08-368950) has been discontinued, effective June 19, 2017.

The effect of this discontinuance is that this lawsuit is concluded, and it will not be proceeding further, and there will be no judgment or settlement in favour of the class.   Furthermore, any limitation periods that had been suspended in favour of class members under s.28(1) of the Class Proceedings Act will commence running again from the effective date of the discontinuance.

An Account of the Proceeding

This lawsuit had been certified by Ontario Superior Court of Justice, dated June 21, 2012, in respect of the following class:

“All persons in Canada: (a) who took Champix during the period from April 2, 2007 to May 31, 2010 and (b) who, while taking or after taking Champix to help quit smoking, experienced any of the psychiatric adverse events or symptoms listed below:

  • thoughts about suicide or dying
  • attempts to commit suicide
  • new or worse depression, anxiety or panic attacks
  • feeling very agitated or restless
  • acting aggressive, being angry or violent
  • acting on dangerous impulses
  • an extreme increase in activity and talking (mania)
  • abnormal thoughts or sensations
  • seeing or hearing things that are not there (hallucinations)
  • feeling people are against you (paranoia)
  • feeling confused
  • other unusual changes in behaviour

(the “Class”);

All persons who by reason of his or her relationship to a member of the Class are entitled to make claims under any of the Dependents Statutes in Canada as a result of the death of personal injury of such member of the Class (the “Family Class”);

All provincial or territorial health insurers who are entitled to assert a claim pursuant to the Hospitals Act, R.S.A. 2000, c. H-12, s.62 and related provincial and territorial legislation (“Health Insurer Class”).”

Class Counsel has determined that the class would not be successful at a common issues trial, and that the available scientific and regulatory evidence does not support the representative plaintiff’s allegations.  In particular, a large randomized double-blinded, active- and placebo-controlled trial to compare the risk of clinically significant neuropsychiatric events, including but not limited to suicidality, in individuals using varenicline, and other smoking cessation products did not find an increased risk of neuropsychiatric adverse events associated with Champix.  See: Anthenelli et al, “Neuropyschiatric safety and efficacy of varenicline, buropropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomized, placebo controlled clinical trial”, Lancet, Vol 387, No. 10037, pp.2507-2520, 18 June 2016.

For More Information:

You can contact class counsel at the following addresses:

Ontario                                                            Quebec

McPhadden Samac Tuovi                              Trudel Johnston Lespérance

Suite 300 – 8 King Street East                       Suite 90 – 750, Côte de la Place d’Armes

Toronto, ON, M5C 1B5                                   Montreal, QC H2Y 2X8

Tel: 416-601-1020                                           Tel: 514-871-8385                                        


British Columbia                                             Alberta

Klein Lawyers                                                 Docken & Company

Suite 400 – 1385 West 8th Ave                      Suite 101 – 440 2nd Ave SW

Vancouver, BC V6H 3V9                                Calgary, AB T2P 5E9

Tel: 604-874-7171                                           Tel: 403-269-8246